[{"id":"servier","kind":"company","name":"Servier","route":"/companies/servier/","commit":"067761977c","date":"2026-09-10","author":"Jude Gomila","message":"Sources: official-website links on every remaining company","file":"src/data/companies.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"Official website\", url: \"https://servier.com\" }]"}]},{"id":"servier","kind":"company","name":"Servier","route":"/companies/servier/","commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/sponsor-aliases.ts","type":"added","fields":[{"field":"id"},{"field":"label"},{"field":"kind"}]},{"id":"servier","kind":"company","name":"Servier","route":"/companies/servier/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/companies.ts","type":"changed","fields":[{"field":"tldr","before":"\"Private French pharma that brought vorasidenib, the first low-grade glioma drug, to market.\"","after":"\"Servier is the private French pharma that brought vorasidenib, the first low-grade glioma drug, to market.\""}]}]